Evidence map›Paper›PMID 22033509›Full record

ReviewDialogues in clinical neuroscience2011

Is progesterone a worthy candidate as a novel therapy for traumatic brain injury?

Donald G Stein

Abstract readReview
In one paragraph

Review in Dialogues in clinical neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Sex and Gender Science: The World Writes on the Body.Current topics in behavioral neurosciences · 2023
    Article
  3. Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant.International journal of molecular sciences · 2020
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Investigational agents for treatment of traumatic brain injury.Expert opinion on investigational drugs · 2015
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Therapy in pediatric stroke.European journal of pediatrics · 2013
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Donald G SteinDepartment of Emergency Medicine, Emory University, Atlanta, Georgia 30822, USA. dstei04@emory.edu
Emory University · US

Funding

British Heart Foundation
6 · The paper itself

Abstract

Although progesterone is critical to a healthy pregnancy, it is now known to have other important functions as well. Recent research demonstrates that this hormone is also a potent neurosteroid that can protect damaged cells in the central and peripheral nervous systems and has rapid actions that go well beyond its effects on the classical intranuclear progesterone receptor. Based on years of preclinical research demonstrating its safety and effectiveness in animal models of central nervous system injury the hormone was recently tested in two Phase II clinical trials for traumatic brain injury (TBI). A US National Institutes of Health-sponsored, nationwide Phase III clinical trial is now evaluating progesterone for moderate-to-severe TBI in 1200 patients. An industry-sponsored Phase III international trial is also under way, and planning for a trial using progesterone to treat pediatric brain injury has begun. Preclinical data suggest that progesterone may also be effective in stroke and some neurodegenerative disorders.

Indexed as

AnimalsBrain InjuriesHumansProgesteroneProgestinsProgesteroneProgestinsneuroprotectionprogesteronetraumatic brain injury

Identifiers

PMID22033509
PMCPMC3182014
OpenAlexW127022127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.